From: Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies
Risk factors | urgent/emergent surgery n = 131 | elective surgery n = 351 | p- value | OR (95%CI) |
---|---|---|---|---|
Gender male | 88(67.1) | 228(64.9) | 0.64 | 1.10 (0.72-1.69) |
Age at initial surgery < 44 years | 80(61.1) | 158(45.0) | <0.01* | 1.92 (1.28-2.89) |
Age at onset of UC < 32 years | 55(41.9) | 181(51.6) | 0.06 | 0.68 (0.45-1.02) |
Duration of disease < 70 months | 105(80.2) | 136(38.7) | <0.01* | 6.38 (3.95-10.32) |
Severe/Fulminant disease | 118(90.1) | 27(7.7) | <0.01* | 108.9 (56.3-2227.1) |
Rectal sparing type | 24(18.3) | 22(6.3) | <0.01* | 3.35 (1.81-6.26) |
Total given PSL dose <5000 mg | 91(69.5) | 132(37.6) | <0.01* | 3.77 (2.46-5.80) |
Daily pre-operative PSL dose ≥ 9 mg/day | 103(78.6) | 139(39.6) | <0.01* | 5.61 (3.55-9.11) |
Immunomodulators | ||||
TAC/CsA | 39(29.8) | 84(23.9) | 0.19 | 1.35 (0.86-2.09) |
AZA/6-MP | 16(12.2) | 108(30.8) | <0.01* | 0.32 (0.17-0.54) |
Biologics administration | 33(25.2) | 194(55.3) | 0.72 | 1.08 (0.68-1.72) |